EGFR and lung carcinoma: We recently showed in a large series of lung cancer patients that besides allowing the identification of EGFR, KRAS, and BRAF mutations, NGS identified a potential driver in 36% of patients (FGFR, ERBB2, AKT, MAP2K1, STK11...) [14,94,95,96].